Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimix DC and TLR-DC intranodal vaccination in stage III and IV melanoma
2009-015737-73Phase 2Suspended
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2009
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of TriMix-DC in melanoma (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Toxicity of intranodally injected Trimix DC and TLR-DC by dose escalation of dendritic cell numbers and Immunological responses upon TLR-DC vaccination. Started Sep 2009; status: suspended.
02
Drugs
TriMix-DC
03
Conditions
melanoma
Beyond the preview
Go deeper on 2009-015737-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015737-73.